What Baralgan-D Treats: Main Uses and Benefits

Baralgan-D is relevant for easing certain symptoms related to heightened physiological activity across several key domains. It is utilized when symptoms are associated with acute or episodic changes and discomfort.

Quick Fact: Relief for Smooth Muscle Spasms

This medication is commonly used to help with symptoms of increased neurological or muscular activity. These include spasms linked to biliary tract disorders, urinary tract conditions, functional gastrointestinal spasms, and gynecological cramping (dysmenorrhea).

The primary therapeutic domain is relevant for easing symptoms linked to organ-specific functional stress. This approach provides support that helps ease the overall symptom burden associated with acute or disruptive episodes, and supports general well-being during symptomatic phases. It contributes to improved comfort during periods of heightened symptoms, which provides supportive relief when symptoms interfere with routine activities.

Regulatory References

1. Swiss Public Assessment Report

Baralgan-D’s population eligibility is defined by regulatory criteria that establish absolute contraindications and restrictions based on underlying health status. The medicine is absolutely contraindicated in patients with severe dysfunction of key organs, including severe cardiac, hepatic, or renal failure, or those with known hypersensitivity to the active component. Further absolute exclusions involve specific cardiovascular conditions such as AV Blockade II and III grades, cardiogenic shock, and the rare blood disorder Porphyria.

Eligibility is restricted for certain age groups; the medicine is generally not recommended for use in children below 12 years of age, and safety data is insufficient for use in children under six years. Use is also restricted during specific physiological states: it is not recommended in official labeling for individuals who are pregnant or breastfeeding, due to the lack of established safety data in these populations. Additionally, special caution is advised for patients with arterial hypotension or those concurrently taking Levodopa.

Interaction Scope

The official regulatory documentation for Drotaverine hydrochloride primarily identifies interactions based on pharmacodynamic and effect-altering mechanisms, without detailing specific enzyme-mediated (CYP) or transporter-based interactions.

Category	Documented Interaction Statement
Specific Interacting Medicines	Levodopa; Morphine; Patent Blue; Phenobarbital.
Substance Interactions	Alcohol.
Medicinal Product Categories	Other Spasmolytics; Agents causing Hypotension (e.g., tricyclic antidepressants, quinidine, Riociguat).

Official Interaction Statements

• Levodopa: Co-administration is officially documented to reduce the antiparkinsonian activity of Levodopa, which can result in increased rigidity and tremor. This combination often warrants regulatory restriction.
• Other Spasmolytics: Drotaverine is noted to intensify or enhance the effect of other spasmolytic agents, including those with anticholinergic properties.
• Hypotension-Causing Agents: The medicine is documented to enhance the hypotensive activities of agents such as quinidine, procainamide, and certain tricyclic antidepressants, increasing their overall vasodilatory effect.
• Morphine: Drotaverine officially reduces the spasmogenic activity of the opioid analgesic Morphine.
• Patent Blue: The co-administration of this dye is documented to decrease the therapeutic efficacy of Drotaverine.
• Alcohol: Concomitant use with alcohol is noted in regulatory-aligned information due to the potential for increased dizziness.

The regulatory profile emphasizes potential antagonistic outcomes (Levodopa) and additive outcomes (Hypotension-causing agents), forming the main structure of the drug's official interaction constraints.

How Baralgan-D Works

The action of Drotaverine hydrochloride is defined by its selective mechanism as a myotropic antispasmodic, influencing the contractile process of smooth muscle cells through a dual molecular mechanism. This action is predominantly peripheral and proceeds without the involvement of the central nervous system or anticholinergic pathways.

---

Selective Inhibition of PDE4 and cAMP Modulation

The primary action involves the non-competitive inhibition of the enzyme Phosphodiesterase 4 ( PDE4), which is highly prevalent in visceral smooth muscle. By blocking PDE4, the drug causes the cellular messenger, cyclic Adenosine Monophosphate ( cAMP), to accumulate. This elevated cAMP initiates a cascade that inactivates the Myosin Light-Chain Kinase ( MLCK) enzyme. This pathway adjustment is significant because MLCK is the primary enzyme required to initiate muscle contraction.

---

Regulation of Intracellular Calcium Dynamics

Complementing the enzyme inhibition, the drug also modulates the availability of intracellular calcium ( Ca^2+). It achieves this by exerting a secondary blocking effect on L-type Voltage-Dependent Calcium Channels ( L-VDCCs). Since Ca^2+ influx is the fundamental signal for muscle contraction, limiting its availability further dampens the muscle cell's capacity for contraction. The combined effect of elevated cAMP and reduced free Ca^2+ leads the targeted muscle tissue toward a relaxed state, modulating hyperactivity. The mechanism is purely spasmolytic and constrained to influencing smooth muscle contraction.

Baralgan-D is administered through two primary routes: oral via tablets and parenteral via solution for injection. This dual route allows for differentiated use based on the required speed of action and setting. The oral form is manufactured in 40 mg and 80 mg strengths.

For adult use, the established principle is a total daily administration ranging from 120 mg to 240 mg, which must be divided into two or three separate doses per day. Administration of the tablets is possible either with or without food, though the tablets must be swallowed whole to adhere to the labeled instructions; they are not intended to be crushed or broken.

The medicine is intended for symptomatic, short-term management, and the frequency pattern dictates a highly controlled approach to the total daily intake. The injectable solution is reserved for acute needs and is administered by a healthcare professional via the intramuscular or intravenous route, with single doses typically ranging from 40 mg to 80 mg up to three times daily.

Specific dose ceilings are established for pediatric administration. For children aged 6 to 12 years, the maximum daily intake is limited to 80 mg across two doses. For children older than 12 years, the maximum daily limit is 160 mg administered in two to four separate doses. This structural approach ensures usage remains within dosage limits across different age groups.

Research Evidence / Overview of Studies for Baralgan-D

This overview summarizes the available research on Drotaverine hydrochloride, the active component in Baralgan-D. The text describes what types of studies have been conducted for its core uses, what outcomes were examined, and where scientific uncertainties or limitations exist. The information is based only on findings reported in official and peer-reviewed sources and should not be used for clinical guidance.

---

Evidence for Use in Functional Gastrointestinal Spasms

Research has examined this medicine in studies relevant to adults with conditions characterized by fluctuating or episodic manifestations, such as Irritable Bowel Syndrome (IBS). The studies that examined this area include Randomized Controlled Trials (RCTs) and other observational studies.

Studies primarily measured changes in pain severity and the frequency of painful episodes. Studies also explored functional outcomes, such as changes in stool consistency and frequency. Findings describe patterns observed in the studies over these short intervals, and changes measured during the study period were reported for the specific groups observed.

---

Evidence for Pain in Colic (Renal, Ureteric, and Biliary)

The medicine was evaluated in research relevant to conditions involving periods of increased symptom activity related to the urinary tract (renal and ureteric colic) and the biliary tract. The evidence here primarily comes from acute, short-term Randomized Controlled Trials.

These studies explored outcomes related to physical discomfort by measuring the intensity of pain and the time it took for symptoms to change after administration. Researchers also monitored the need for additional pain medication (rescue medication). The data indicate patterns related to changes in pain intensity within the hours immediately following a single dose. Reported outcomes focused on measured changes during short time intervals and not on long-term disease progression.

---

What is Still Uncertain About Baralgan-D Research

The body of research highlights what is known—and what is still uncertain. Scientific reviews indicate several areas where research is ongoing or needs further development:

• Long-Term Outcomes: There is limited information on the long-term effects, durability of response, or safety profile beyond short-term follow-up durations.
• Data Quality and Age: Scientific reviews have noted a paucity of recent, large-scale studies. Many of the existing foundational studies are considered dated, and evidence quality varies across studies.
• Subgroup Findings: Comparative evidence is lacking for some of the medicine's uses, and subgroup findings are uncertain for specific patient profiles. Research provides context but not individual predictions.

Key Studies & References

1. Efficacy and safety of combination therapy with drotaverine and ketorolac versus ketorolac monotherapy for acute renal colic: a retrospective study of 322 patients
2. Drotaverine in Dysmenorrhoea Treatment (Clinical Trial NCT00292747)
3. Swiss Public Assessment Report (SwissPAR) for Spaverin (Drotaverine hydrochloride)

Common questions about Baralgan-D (FAQ)

---

Q: Is Baralgan-D the same as a regular painkiller?

No. According to official classifications, Baralgan-D is a myotropic antispasmodic agent. Its primary function is to provide relief by relaxing the smooth muscles in internal organs. This mechanism is different from that of general pain relievers, or analgesics, which work through separate pathways to address pain.

---

Q: Does Baralgan-D contain a narcotic ingredient?

Official documents indicate that the active ingredient, drotaverine hydrochloride, is a synthetic chemical compound. It is specifically classified as an antispasmodic agent. Baralgan-D is not classified as a narcotic or controlled substance.

---

Q: How quickly does Baralgan-D typically start working?

Official drug labels indicate that for the oral tablet form, the medicine usually reaches its highest level in the bloodstream within 1 to 3 hours. This time frame indicates when the concentration of the medicine typically peaks in the bloodstream. The solution for injection is noted to have a faster onset of action.

---

Q: How long does the effect of Baralgan-D usually last?

Reports on the drug's properties indicate an average elimination half-life generally ranging from 7 to 16 hours. This measurement describes the time it takes for half the substance to leave the body. The duration of symptomatic relief for spasm-related discomfort may vary by individual.

---

Q: Is Baralgan-D a prescription-only medicine?

The regulatory classification of this medicine can vary significantly depending on the country. In some regions, the tablet form may be available without a prescription (Over-The-Counter). However, the injectable solution is generally restricted to use by a healthcare professional.

---

Q: Is there a generic version of Baralgan-D available?

Yes. The active ingredient, Drotaverine hydrochloride, is manufactured and sold by various companies worldwide. This means the same active substance can be found globally under many different brand names, which are considered generic alternatives.

---

Q: What are the signs of an allergic reaction to Baralgan-D?

Official regulatory documents warn that rare, severe allergic responses (hypersensitivity) can occur. Recognized signs may include a rash, itching, and localized swelling, such as of the face or throat. Extremely rare and serious reactions like difficulty breathing (bronchospasm) have also been reported.

---

Q: Why is Baralgan-D sometimes combined with other ingredients?

The product specifically known as Baralgan-D contains only the single active substance, Drotaverine hydrochloride. The active ingredient, drotaverine, is frequently included in combination drug products with other ingredients, such as non-steroidal anti-inflammatory drugs (NSAIDs). These combinations are designed to address both smooth muscle spasm and general pain.

---

Q: What official body regulates Baralgan-D?

The active component, drotaverine hydrochloride, is regulated by national government drug authorities across many countries where it is commonly approved. Since this drug is not widely approved in the U.S. or EU, its regulatory oversight comes from bodies like Swissmedic and the government agencies of other specific nations.

---

Q: Is Baralgan-D mentioned in clinical guidelines for certain conditions?

Official regulatory reviews and studies indicate that the drug has been researched in populations relevant to the treatment of smooth muscle spasms. This includes conditions like Irritable Bowel Syndrome (IBS) and abdominal discomfort associated with different types of colic, such as renal or biliary.

---

Q: What happens if I miss a dose of Baralgan-D?

Patient information leaflets describe a procedure for a missed dose. If a dose is forgotten, the leaflet generally states to take it upon remembering. If it is close to the next scheduled dose, the instruction is typically to skip the missed one. The leaflets officially state that taking two doses to compensate is not recommended.

---

Q: What does 'contraindication' mean in the context of Baralgan-D?

A contraindication is an official term used in regulatory documents to describe a condition or circumstance where the use of the medicine is officially restricted or prohibited. For Baralgan-D, this includes specific serious health issues like severe heart, liver, or kidney failure, as the use could carry an unacceptable risk.

---

Q: Is it normal if I don't feel any effect immediately after taking Baralgan-D?

Yes, this is generally consistent with the medicine's properties. Because the oral tablet can take between 1 to 3 hours to reach its maximum concentration in the blood, the peak drug concentration in the body may not be apparent immediately. Administration by injection is generally associated with a faster onset of action due to the route of delivery.

---

Q: Is Baralgan-D suitable for patients who are lactose intolerant?

Many commercially available tablet forms of drotaverine hydrochloride contain lactose monohydrate as an inactive component (excipient). Official labeling states the importance of reviewing the product packaging for a full list of inactive ingredients.

---

Q: Are there any studies on Baralgan-D use in people with kidney issues?

Official safety information does not detail specific studies in patients with severe kidney issues, but it does list severe renal insufficiency as a contraindication. This suggests that the kidney's role in processing the drug is significant and its use is restricted in patients with this condition.

---

Q: What does 'pharmacovigilance' mean for Baralgan-D?

Pharmacovigilance refers to the official system used by regulatory bodies to continuously monitor the medicine's safety after it has been approved. This system collects and tracks reports of new or unexpected side effects. This ensures that the safety information about the drug remains current.

The storage and disposal of Baralgan-D must adhere strictly to the conditions specified in official regulatory labeling to ensure product quality and safety.

Storage Requirements

Condition	Regulatory Stipulation
Temperature	Store at a temperature not exceeding 30 C
Protection	Protect from light and moisture; store in a cool, dry place
Packaging	Store in the original packaging and keep the container tightly closed
Safety	Keep out of the reach of children and pets

Disposal Instructions

To dispose of Baralgan-D, do not use the product after the expiry date printed on the packaging. Any unused or expired medicine must be disposed of in accordance with local/national regulations and the instructions provided on the pack. This process ensures the product is not released into drains or the environment and is not consumed by others.